AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1535653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 922
Study 6532586 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of a specific vasopressin antagonist acting at the vascular site
Number of subjects: 0
Study 6532586 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 0
Study 30460746 — intervention group
Group type: EXPERIMENTAL
Intervention: First spectacles for myopia (SE ≤ -6.00 D in either eye)
Number of subjects: 240
Study 30460746 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental myopia
Number of subjects: 240
Study 30460746 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age at baseline
Number of subjects: 240
Study 30460746 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher myopia at baseline
Number of subjects: 240
Study 30460746 — intervention group
Group type: EXPERIMENTAL
Intervention: More time spent on reading and close work
Number of subjects: 240
Study 30460746 — intervention group
Group type: EXPERIMENTAL
Intervention: Less time spent outdoors
Number of subjects: 240
Study 27923475 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric orthopedists (Group A)
Number of subjects: 88
Study 27923475 — intervention group
Group type: COMPARATOR
Intervention: Non-pediatric orthopedists (Group B)
Number of subjects: 88
Study 27923475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 88
Study 25336324 — intervention group
Group type: EXPERIMENTAL
Intervention: LM low viscosity pectin beverage
Number of subjects: 25
Study 25336324 — intervention group
Group type: EXPERIMENTAL
Intervention: LM high viscosity pectin beverage
Number of subjects: 25
Study 25336324 — intervention group
Group type: EXPERIMENTAL
Intervention: HM low viscosity pectin beverage
Number of subjects: 25
Study 25336324 — intervention group
Group type: EXPERIMENTAL
Intervention: HM high viscosity pectin beverage
Number of subjects: 25
Study 25336324 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA pectin beverage
Number of subjects: 25
Study 24709034 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000U of rimabotulinumtoxinB (n=8)
Number of subjects: 24
Study 24709034 — intervention group
Group type: EXPERIMENTAL
Intervention: 15,000U of rimabotulinumtoxinB (n=8)
Number of subjects: 24
Study 22439244 — intervention group
Group type: COMPARATOR
Intervention: Plates (group A)
Number of subjects: 97
Study 22439244 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable screws (group B)
Number of subjects: 97
Study 19568205 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 103
Study 19568205 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 103
Study 19568205 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise training
Number of subjects: 103
Study 19568205 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 103
Study 17276802 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized emergency nurses (SENs)
Number of subjects: 512
Study 17276802 — intervention group
Group type: COMPARATOR
Intervention: House officers (HOs)
Number of subjects: 512
Study 15247733 — intervention group
Group type: EXPERIMENTAL
Intervention: 12/15Fr Applied Access Forte XE (Applied Medical)
Number of subjects: 54
Study 15247733 — intervention group
Group type: COMPARATOR
Intervention: 12/14Fr Cook Flexor (Cook Urological)
Number of subjects: 54
Study 12202470 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 1806
Study 9578335 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (7.4 g)
Number of subjects: 14
Study 9578335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7523130 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant hormonal treatment with GnRH analogue (triptorelin) for 3 months
Number of subjects: 56
Study 7523130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormonal treatment)
Number of subjects: 56
Study 2694858 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil combination anaesthesia
Number of subjects: 50
Study 2694858 — intervention group
Group type: COMPARATOR
Intervention: Ethrane inhalation anaesthesia
Number of subjects: 50
Study 902677 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin alone (preparation C)
Number of subjects: 12
Study 902677 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin-antacid combination (preparation A)
Number of subjects: 12
Study 902677 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin-antacid combination (preparation B)
Number of subjects: 12
Study 30272192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary nodule detection
Number of subjects: 269
Study 30272192 — intervention group
Group type: COMPARATOR
Intervention: Normal CT group
Number of subjects: 269
Study 28146251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268
Study 28146251 — intervention group
Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 268
Study 25805645 — intervention group
Group type: EXPERIMENTAL
Intervention: l-DOPA
Number of subjects: 61
Study 25805645 — intervention group
Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 61
Study 25086659 — intervention group
Group type: EXPERIMENTAL
Intervention: RIS+OLZ (augmentation with olanzapine)
Number of subjects: 60
Study 25086659 — intervention group
Group type: COMPARATOR
Intervention: RIS-OLZ (switching to olanzapine)
Number of subjects: 60
Study 25086659 — intervention group
Group type: EXPERIMENTAL
Intervention: OLZ-RIS (augmentation with risperidone)
Number of subjects: 60
Study 25086659 — intervention group
Group type: COMPARATOR
Intervention: OLZ+RIS (switching to risperidone)
Number of subjects: 60
Study 22458865 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 week high-load strength training program
Number of subjects: 0
Study 22458865 — intervention group
Group type: COMPARATOR
Intervention: Maintain habitual activity level (Control)
Number of subjects: 0
Study 19640677 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral family-based therapy (CBFT)
Number of subjects: 38
Study 19640677 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral family-based therapy (CBFT)
Number of subjects: 38
Study 17714334 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BTX) treatment
Number of subjects: 9
Study 17714334 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 9
Study 14615876 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (PY) - 45 microg/kg (very low dose)
Number of subjects: 8
Study 14615876 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (PY) - 115 microg/kg (low dose)
Number of subjects: 8
Study 14615876 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (PY) - 215 microg/kg (medium dose)
Number of subjects: 8
Study 14615876 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (PY) - 315 microg/kg (high dose)
Number of subjects: 8
Study 14615876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study 11437771 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) at 7.5 cmH2O
Number of subjects: 20
Study 11437771 — intervention group
Group type: COMPARATOR
Intervention: Standard technique using Mapleson A breathing system
Number of subjects: 20
Study 11437771 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Number of subjects: 20
Study 9728858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (inspired nitrous oxide >50%)
Number of subjects: 20
Study 9728858 — intervention group
Group type: COMPARATOR
Intervention: Non-nitrous oxide
Number of subjects: 20
Study 8166470 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0
Study 3056751 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormono-chemotherapy (Tamoxifen for 6 months, and 6-monthly cycles of vincristine, adriamycin, and cyclophosphamide)
Number of subjects: 157
Study 3056751 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant therapy)
Number of subjects: 157
Study 519956 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (single oral dose)
Number of subjects: 5
Study 31602811 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept and navigated laser (group A)
Number of subjects: 37
Study 31602811 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept and conventional laser (group B)
Number of subjects: 37
Study 30278428 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (Simbioflora, Farmoquimica, São Paulo, Brazil)
Number of subjects: 73
Study 30278428 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 73
Study 30278428 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics
Number of subjects: 73
Study 30278428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 27567268 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Abstainers
Number of subjects: 954
Study 25932848 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored, motivationally matched exercise intervention for 12 weeks
Number of subjects: 352
Study 25932848 — intervention group
Group type: COMPARATOR
Intervention: Health and wellness comparison intervention
Number of subjects: 352
Study 28136072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib (800 mg once daily for up to 24 months)
Number of subjects: 940
Study 28136072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 940
Study 28136072 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 940
Study 21932561 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise increase in the extent of combined salmoterol/fluticason therapy
Number of subjects: 543
Study 21932561 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term stable-dose salmoterol/fluticason therapy
Number of subjects: 543
Study 21932561 — intervention group
Group type: COMPARATOR
Intervention: Salmoterol/fluticason therapy with gradual decrease of the dose and/or transition to an alternative variant
Number of subjects: 543
Study 19825213 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented milk containing Lactobacillus acidophilus 145 and Bifidobacterium longum BB536 (125 g three times a day for 4 weeks)
Number of subjects: 34
Study 19825213 — intervention group
Group type: COMPARATOR
Intervention: Regular yoghurt (control group)
Number of subjects: 34
Study 17383282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 900
Study 17383282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 900
Study 15193791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentine bonding agent (DBA) - Prime & Bond NT applied after acid-etching
Number of subjects: 34
Study 15193791 — intervention group
Group type: COMPARATOR
Intervention: Control group - No DBA applied
Number of subjects: 34
Study 10678381 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle valve
Number of subjects: 76
Study 10678381 — intervention group
Group type: COMPARATOR
Intervention: Homograft valve
Number of subjects: 76
Study 9098819 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.01% dexamethasone sodium phosphate drops
Number of subjects: 12
Study 9098819 — intervention group
Group type: COMPARATOR
Intervention: 0.01% timolol maleate drops
Number of subjects: 12
Study 8487598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (90 mg/d)
Number of subjects: 50
Study 8487598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (60 mg/d)
Number of subjects: 50
Study 4037255 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride 1 mg/ml
Number of subjects: 5
Study 4037255 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride 5 mg/ml
Number of subjects: 5
Study 4037255 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride 10 mg/ml
Number of subjects: 5
Study 4037255 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine dihydrochloride (all concentrations)
Number of subjects: 5
Study 31593592 — intervention group
Group type: COMPARATOR
Intervention: Engagement in contemplation group vs. pre‐contemplation group
Number of subjects: 251
Study 31593592 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual degree centrality (comments and likes)
Number of subjects: 251
Study 31593592 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based social media intervention
Number of subjects: 251
Study 31304890 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST) during aplasia, consisting of five 1-hour individual sessions starting 2 days before HSCT.
Number of subjects: 91
Study 31304890 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) without PST.
Number of subjects: 91
Study 29480874 — intervention group
Group type: EXPERIMENTAL
Intervention: EVIDENT 3 application with smartphone and smartband for 3 months
Number of subjects: 700
Study 29480874 — intervention group
Group type: COMPARATOR
Intervention: Traditional primary care lifestyle counseling
Number of subjects: 700
Study 26839144 — intervention group
Group type: EXPERIMENTAL
Intervention: Abituzumab 750 mg
Number of subjects: 180
Study 26839144 — intervention group
Group type: EXPERIMENTAL
Intervention: Abituzumab 1,500 mg
Number of subjects: 180
Study 26839144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 26839144 — intervention group
Group type: EXPERIMENTAL
Intervention: Abituzumab
Number of subjects: 180
Study 25280410 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose supplementation (120 g/d for 3 days)
Number of subjects: 10
Study 25280410 — intervention group
Group type: COMPARATOR
Intervention: Glucose solution (control)
Number of subjects: 10
Study 23236449 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (40% VO2peak)
Number of subjects: 8
Study 23236449 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (80% VO2peak)
Number of subjects: 8
Study 23236449 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 8
Study 19357861 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol
Number of subjects: 235
Study 19357861 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist protocol
Number of subjects: 235
Study 18066449 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 57
Study 18066449 — intervention group
Group type: COMPARATOR
Intervention: Ventilation with two pressure levels (PEEP + SP)
Number of subjects: 57
Study 18066449 — intervention group
Group type: COMPARATOR
Intervention: BiPAP
Number of subjects: 57
Study 18066449 — intervention group
Group type: EXPERIMENTAL
Intervention: NIV application
Number of subjects: 57
Study 16295154 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus 3 hours contact with a pediatric nurse practitioner (PNP) for counseling, instruction, and assistance with implementation of the recommended treatment plan
Number of subjects: 31
Study 16295154 — intervention group
Group type: COMPARATOR
Intervention: Usual care (1-hour consultation session and written treatment plan)
Number of subjects: 31
Study 12505250 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5804
Study 12505250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5804
Study 9529267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-chamber atrial pacing
Number of subjects: 225
Study 9529267 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber ventricular pacing
Number of subjects: 225
Study 7639973 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural interventions for HIV/AIDS prevention
Number of subjects: 68
Study 2136939 — intervention group
Group type: COMPARATOR
Intervention: Ramipril
Number of subjects: 7
Study 323454 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 0
Study 323454 — intervention group
Group type: EXPERIMENTAL
Intervention: Picloxydine mouthwash (higher concentration)
Number of subjects: 0
Study 30724574 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-Oriented Attentional Self-Regulation training (GOALS)
Number of subjects: 30
Study 30724574 — intervention group
Group type: COMPARATOR
Intervention: Brain Health Education program (BHE)
Number of subjects: 30
Study 30724574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 30217118 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab alone
Number of subjects: 47
Study 30217118 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab plus teriparatide
Number of subjects: 47
Study 28395131 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate containing 50 mg elemental zinc daily for 12 weeks)
Number of subjects: 60
Study 24916837 — intervention group
Group type: EXPERIMENTAL
Intervention: Path analysis model
Number of subjects: 2524
Study 24916837 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent processing the cancer experience
Number of subjects: 2524
Study 24916837 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer worry
Number of subjects: 2524
Study 23686379 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care + daily CP mouth rinses (n=27)
Number of subjects: 60
Study 23686379 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (n=31)
Number of subjects: 60
Study 22139337 — intervention group
Group type: EXPERIMENTAL
Intervention: Betacarotene (BC) group supplemented daily with 50 mg of BC (n=9; LW: 17.3±1.0 kg; BCS: 3.34±0.12)
Number of subjects: 17
Study 22139337 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONT; n=8; LW: 16.1±1.0 kg; BCS=3.17±0.12)
Number of subjects: 17
Study 19109408 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg in pellet form
Number of subjects: 0
Study 19109408 — intervention group
Group type: COMPARATOR
Intervention: Control (no orlistat)
Number of subjects: 0
Study 17003088 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 226
Study 17003088 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin (sc insulin)
Number of subjects: 226
Study 15285598 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled scientific causal thinking simulation
Number of subjects: 0
Study 11261319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g once daily plus tobramycin 5 mg/kg
Number of subjects: 114
Study 11261319 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime 2 g three times daily plus tobramycin 5 mg/kg
Number of subjects: 114
Study 9249099 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg intravenous ibuprofen
Number of subjects: 52
Study 9249099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 8034237 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU unfractionated (UF) heparin
Number of subjects: 60
Study 8034237 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500 activated partial thromboplastin time units low molecular mass (LMM) heparin
Number of subjects: 60
Study 8034237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2894979 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5, 10, 20 mg bid)
Number of subjects: 22
Study 2894979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (1, 2, 4 mg bid)
Number of subjects: 22
Study 2894979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2894979 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg/day)
Number of subjects: 22
Study 2894979 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 degrees tilt
Number of subjects: 22
Study 29490090 — intervention group
Group type: EXPERIMENTAL
Intervention: Common bean flour
Number of subjects: 331
Study 29490090 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted cowpea
Number of subjects: 331
Study 29490090 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend (control)
Number of subjects: 331
Study 28069096 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day simulation course
Number of subjects: 37
Study 26512149 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcin tablets 1,500 mg daily for 7 days
Number of subjects: 110
Study 26512149 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole tablets 150 mg daily for 7 days
Number of subjects: 110
Study 23221480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with tamsulosin (0.4 mg) and fesoterodine extended-release
Number of subjects: 47
Study 23221480 — intervention group
Group type: COMPARATOR
Intervention: Single administration of tamsulosin (0.4 mg)
Number of subjects: 47
Study 21891972 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg IV infusion)
Number of subjects: 24
Study 21891972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17368873 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (150mg/day of CoQ(10) for four weeks)
Number of subjects: 40
Study 17368873 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 40
Study 16868359 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg dried garlic powder
Number of subjects: 20
Study 16868359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12624611 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle intervention in a rehabilitation centre for 12 months
Number of subjects: 731
Study 12624611 — intervention group
Group type: COMPARATOR
Intervention: Usual care in an occupational or primary health-care centre for 12 months
Number of subjects: 731
Study 10487669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration at 1700 h
Number of subjects: 9
Study 10487669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration at 0500 h
Number of subjects: 9
Study 10487669 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 9